New Leaf Venture Partners Closes $450 Million Healthcare Fund
NEW YORK & MENLO PARK, Calif.–Oct. 10, 2007–New Leaf Venture Partners, L.L.C. (“NLV Partners”) today announced the closing of New Leaf Ventures II, L.P. (“NLV-II”), a $450 million venture capital fund dedicated to healthcare technologies. With strong support from existing investors and a limited number of new investors, NLV-II exceeded its $400 million target and closed at its hard cap of investor commitments.
With NLV-II, NLV Partners will continue to invest primarily in firms that are focused on clinical-stage biopharmaceutical products, early-stage medical devices, and molecular diagnostics. Since the inception of New Leaf Ventures I, L.P. (“NLV-I”) in 2005, the NLV Partners team has invested in 19 companies including Cerexa, the first realization from the NLV-I portfolio. They have also had recent notable exits from investments in Ilypsa, Adeza BioMedical, Phase Forward and Sirna Therapeutics.
The NLV Partners team includes: Managing Directors Philippe Chambon, M.D., Ph.D., Ron Hunt and James Niedel, M.D., Ph.D., and CFO Craig Slutzkin in the firm’s New York office; and Managing Directors Jeani Delagardelle, Kathy LaPorte and Vijay Lathi, and Venture Partner Milt McColl in the firm’s Menlo Park office.
About NLV Partners
NLV Partners is a life science-dedicated venture capital firm with offices in Menlo Park and New York. Founded by an experienced team of venture capitalists with deep healthcare industry experience, NLV Partners invests primarily in companies focused on clinical-stage biopharmaceutical products, early-stage medical devices, and molecular diagnostics. NLV Partners manages over $1.3 billion of assets, including NLV-I, NLV-II and the healthcare technology portfolio of Sprout Group. For further information, visit the NLV Partners website at www.nlvpartners.com.
Burns McClellan, New York
on Behalf of NLV Partners
Justin Jackson, 212-213-0006, Ext. 327